33,333,334 Shares of Common Stock ImmunityBio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 11th, 2024 • ImmunityBio, Inc. • Biological products, (no disgnostic substances) • New York
LIMITED CONSENT AND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT December 10, 2024Revenue Interest Purchase Agreement • December 11th, 2024 • ImmunityBio, Inc. • Biological products, (no disgnostic substances)
This LIMITED CONSENT AND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT (this “Consent”), dated as of the date first set forth above, is entered into by and among ImmunityBio, Inc., a Delaware corporation (the “Company”), the Persons listed on the signature pages hereof under the heading “PURCHASERS”, which constitute the Required Purchasers in accordance with Section 8.08(a) of the Purchase Agreement (each a “Purchaser” and, collectively, the “Purchasers”), and Infinity SA LLC, a Delaware limited liability company, as collateral agent and administrative agent for the Purchasers (“Purchaser Agent”).
ContractNote • December 11th, 2024 • ImmunityBio, Inc. • Biological products, (no disgnostic substances) • California
THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
